Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.
Cell-free DNA
Circulating tumour DNA
Circulating tumour cells and clusters
Liquid biopsy
Non-small cell lung cancer
Progression-free-survival
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
22
03
2022
revised:
11
05
2022
accepted:
13
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12-18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients. CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.
Sections du résumé
Background
UNASSIGNED
Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12-18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients.
Methods
UNASSIGNED
CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T
Results
UNASSIGNED
Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T
Conclusions
UNASSIGNED
Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.
Identifiants
pubmed: 35874074
doi: 10.1016/j.heliyon.2022.e09971
pii: S2405-8440(22)01259-2
pmc: PMC9305346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e09971Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Oncol. 2011;2011:252361
pubmed: 21577258
Anal Cell Pathol (Amst). 2018 Feb 27;2018:3506874
pubmed: 29682444
Lung Cancer. 2012 Feb;75(2):242-7
pubmed: 21820198
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
Oncotarget. 2016 Jul 12;7(28):44583-44595
pubmed: 27323821
Ann Transl Med. 2017 Feb;5(3):46
pubmed: 28251125
Clin Lung Cancer. 2017 Sep;18(5):583-588
pubmed: 28341106
Cells. 2019 Aug 01;8(8):
pubmed: 31374957
Diagnostics (Basel). 2018 Nov 29;8(4):
pubmed: 30501041
J Thorac Dis. 2018 Apr;10(Suppl 9):S1108-S1112
pubmed: 29850190
Adv Exp Med Biol. 2015;867:341-67
pubmed: 26530376
PLoS One. 2014 Aug 19;9(8):e103883
pubmed: 25137181
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Ann Oncol. 2009 Jul;20(7):1223-9
pubmed: 19282466
Cancer Res. 2014 Mar 15;74(6):1645-50
pubmed: 24448245
Transl Lung Cancer Res. 2020 Oct;9(5):1795-1809
pubmed: 33209602
Clin Lung Cancer. 2018 Mar;19(2):105-114
pubmed: 28935493
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212653
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Ann Transl Med. 2014 Nov;2(11):107
pubmed: 25489581
Cancers (Basel). 2019 Sep 22;11(10):
pubmed: 31546725
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncoimmunology. 2018 Jan 29;7(5):e1424675
pubmed: 29721388
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
Transl Lung Cancer Res. 2016 Oct;5(5):466-482
pubmed: 27826528
Eur Respir Rev. 2020 Feb 12;29(155):
pubmed: 32051167
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Int J Oral Maxillofac Surg. 2021 Aug;50(8):994-998
pubmed: 33358588
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
Clin Chem. 2015 Jan;61(1):259-66
pubmed: 25336717
Sci Rep. 2019 Jan 24;9(1):566
pubmed: 30679441
Diagnostics (Basel). 2018 May 09;8(2):
pubmed: 29747380
Proc Natl Acad Sci U S A. 2016 May 3;113(18):4947-52
pubmed: 27091969
Nat Rev Clin Oncol. 2014 Mar;11(3):129-44
pubmed: 24445517
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Immunother Cancer. 2019 Jul 10;7(1):173
pubmed: 31291995
J Thorac Dis. 2011 Sep;3(3):183-8
pubmed: 22263086
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46
pubmed: 29700092
Br J Cancer. 2011 Oct 25;105(9):1338-41
pubmed: 21970878
Front Oncol. 2021 May 14;11:672687
pubmed: 34055642
Sci Rep. 2017 Feb 15;7:42517
pubmed: 28198401
Lab Chip. 2014 Jan 7;14(1):128-37
pubmed: 23949794
Oncotarget. 2017 Jul 25;8(30):49329-49337
pubmed: 28521303